Quantization of CD34+ peripheral blood hematopoietic progenitors for autografting in cancer patients.
After myeloablative regimens, combined reinfusion of peripheral blood hematopoietic circulating progenitor cells (CPC) and bone marrow, yields a very rapid hematopoietic recovery. Therefore, based on the knowledge that CPC express the CD34 and CD33 differentiation antigen, we have developed a direct immunofluorescence flow cytometry assay to detect the peak of CPC in the peripheral blood of patients treated with high dose chemotherapy and growth factors. This assay, compared to CFU-GM assay, has the following advantages: 1) easy to do 2) standardized method 3) real time information on CPC number. This work illustrates the practical aspects of this assay and substantiate the widespread use of the CD34/33 flow cytometry assay to guide harvesting of circulating hematopoietic progenitors for autologous transplantation.
Di Nicola
M
M
Cristina Gandini Unit, Istituto Nazionale Tumori, Milano, Italy.
Siena
S
S
Bregni
M
M
Peccatori
F
F
Magni
M
M
Ravagnani
F
F
Zorzino
L
L
Bonadonna
G
G
Gianni
A M
AM
D015703:Antigens, CD / Q000032:analysis*; D018952:Antigens, CD34; D000970:Antineoplastic Agents / Q000627:therapeutic use; D003114:Colony-Forming Units Assay; D005434:Flow Cytometry; D005455:Fluorescent Antibody Technique; D018380:Hematopoietic Stem Cell Transplantation; D006412:Hematopoietic Stem Cells / Q000276:immunology; D006801:Humans; D007937:Leukapheresis; D009369:Neoplasms / Q000628:therapy*; D014182:Transplantation, Autologous
D015703:Antigens, CD; D018952:Antigens, CD34; D000970:Antineoplastic Agents